About Golgin subfamily B member 1
Golgin subfamily B member 1 (GOLGB1) is a protein
from Homo sapiens identified by UniProt accession
Q14789, 3259 residues long.
MolForge cross-references it against 0 known binders and
98 disease associations.
Target properties
| Protein name | Golgin subfamily B member 1 |
|---|
| UniProt accession | Q14789 |
|---|
| Gene | GOLGB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3259 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (98)
Diseases linked to this target (Open Targets).
- cancer · score 0.58
- alkaline phosphatase measurement · score 0.35
- mean corpuscular volume · score 0.28
- platelet count · score 0.27
- mean reticulocyte volume · score 0.21
- pancreatic adenocarcinoma · score 0.21
- mean corpuscular hemoglobin concentration · score 0.18
- asthma · score 0.14
- childhood onset asthma · score 0.13
- arterial stiffness measurement · score 0.13
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3259 residues)
MLSRLSGLAN VVLHELSGDD DTDQNMRAPL DPELHQESDM EFNNTTQEDV QERLAYAEQL VVELKDIIRQ KDVQLQQKDE ALQEERKAAD NKIKKLKLHA KAKLTSLNKY IEEMKAQGGT VLPTEPQSEE QLSKHDKSST EEEMEIEKIK HKLQEKEELI STLQAQLTQA QAEQPAQSST EMEEFVMMKQ QLQEKEEFIS TLQAQLSQTQ AEQAAQQVVR EKDARFETQV RLHEDELLQL VTQADVETEM QQKLRVLQRK LEEHEESLVG RAQVVDLLQQ ELTAAEQRNQ ILSQQLQQME AEHNTLRNTV ETEREESKIL LEKMELEVAE RKLSFHNLQE EMHHLLEQFE QAGQAQAELE SRYSALEQKH KAEMEEKTSH ILSLQKTGQE LQSACDALKD QNSKLLQDKN EQAVQSAQTI QQLEDQLQQK SKEISQFLNR LPLQQHETAS QTSFPDVYNE GTQAVTEENI ASLQKRVVEL ENEKGALLLS SIELEELKAE NEKLSSQITL LEAQNRTGEA DREVSEISIV DIANKRSSSA EESGQDVLEN TFSQKHKELS VLLLEMKEAQ EEIAFLKLQL QGKRAEEADH EVLDQKEMKQ MEGEGIAPIK MKVFLEDTGQ DFPLMPNEES SLPAVEKEQA STEHQSRTSE EISLNDAGVE LKSTKQDGDK SLSAVPDIGQ CHQDELERLK SQILELELNF HKAQEIYEKN LDEKAKEISN LNQLIEEFKK NADNNSSAFT ALSEERDQLL SQVKELSMVT ELRAQVKQLE MNLAEAERQR RLDYESQTAH DNLLTEQIHS LSIEAKSKDV KIEVLQNELD DVQLQFSEQS TLIRSLQSQL QNKESEVLEG AERVRHISSK VEELSQALSQ KELEITKMDQ LLLEKKRDVE TLQQTIEEKD QQVTEISFSM TEKMVQLNEE KFSLGVEIKT LKEQLNLLSR AEEAKKEQVE EDNEVSSGLK QNYDEMSPAG QISKEELQHE FDLLKKENEQ RKRKLQAALI NRKELLQRVS RLEEELANLK DESKKEIPLS ETERGEVEED KENKEYSEKC VTSKCQEIEI YLKQTISEKE VELQHIRKDL EEKLAAEEQF QALVKQMNQT LQDKTNQIDL LQAEISENQA IIQKLITSNT DASDGDSVAL VKETVVISPP CTGSSEHWKP ELEEKILALE KEKEQLQKKL QEALTSRKAI LKKAQEKERH LREELKQQKD DYNRLQEQFD EQSKENENIG DQLRQLQIQV RESIDGKLPS TDQQESCSST PGLEEPLFKA TEQHHTQPVL ESNLCPDWPS HSEDASALQG GTSVAQIKAQ LKEIEAEKVE LELKVSSTTS ELTKKSEEVF QLQEQINKQG LEIESLKTVS HEAEVHAESL QQKLESSQLQ IAGLEHLREL QPKLDELQKL ISKKEEDVSY LSGQLSEKEA ALTKIQTEII EQEDLIKALH TQLEMQAKEH DERIKQLQVE LCEMKQKPEE IGEESRAKQQ IQRKLQAALI SRKEALKENK SLQEELSLAR GTIERLTKSL ADVESQVSAQ NKEKDTVLGR LALLQEERDK LITEMDRSLL ENQSLSSSCE SLKLALEGLT EDKEKLVKEI ESLKSSKIAE STEWQEKHKE LQKEYEILLQ SYENVSNEAE RIQHVVEAVR QEKQELYGKL RSTEANKKET EKQLQEAEQE MEEMKEKMRK FAKSKQQKIL ELEEENDRLR AEVHPAGDTA KECMETLLSS NASMKEELER VKMEYETLSK KFQSLMSEKD SLSEEVQDLK HQIEGNVSKQ ANLEATEKHD NQTNVTEEGT QSIPGETEEQ DSLSMSTRPT CSESVPSAKS ANPAVSKDFS SHDEINNYLQ QIDQLKERIA GLEEEKQKNK EFSQTLENEK NTLLSQISTK DGELKMLQEE VTKMNLLNQQ IQEELSRVTK LKETAEEEKD DLEERLMNQL AELNGSIGNY CQDVTDAQIK NELLESEMKN LKKCVSELEE EKQQLVKEKT KVESEIRKEY LEKIQGAQKE PGNKSHAKEL QELLKEKQQE VKQLQKDCIR YQEKISALER TVKALEFVQT ESQKDLEITK ENLAQAVEHR KKAQAELASF KVLLDDTQSE AARVLADNLK LKKELQSNKE SVKSQMKQKD EDLERRLEQA EEKHLKEKKN MQEKLDALRR EKVHLEETIG EIQVTLNKKD KEVQQLQENL DSTVTQLAAF TKSMSSLQDD RDRVIDEAKK WERKFSDAIQ SKEEEIRLKE DNCSVLKDQL RQMSIHMEEL KINISRLEHD KQIWESKAQT EVQLQQKVCD TLQGENKELL SQLEETRHLY HSSQNELAKL ESELKSLKDQ LTDLSNSLEK CKEQKGNLEG IIRQQEADIQ NSKFSYEQLE TDLQASRELT SRLHEEINMK EQKIISLLSG KEEAIQVAIA ELRQQHDKEI KELENLLSQE EEENIVLEEE NKKAVDKTNQ LMETLKTIKK ENIQQKAQLD SFVKSMSSLQ NDRDRIVGDY QQLEERHLSI ILEKDQLIQE AAAENNKLKE EIRGLRSHMD DLNSENAKLD AELIQYREDL NQVITIKDSQ QKQLLEVQLQ QNKELENKYA KLEEKLKESE EANEDLRRSF NALQEEKQDL SKEIESLKVS ISQLTRQVTA LQEEGTLGLY HAQLKVKEEE VHRLSALFSS SQKRIAELEE ELVCVQKEAA KKVGEIEDKL KKELKHLHHD AGIMRNETET AEERVAELAR DLVEMEQKLL MVTKENKGLT AQIQSFGRSM SSLQNSRDHA NEELDELKRK YDASLKELAQ LKEQGLLNRE RDALLSETAF SMNSTEENSL SHLEKLNQQL LSKDEQLLHL SSQLEDSYNQ VQSFSKAMAS LQNERDHLWN ELEKFRKSEE GKQRSAAQPS TSPAEVQSLK KAMSSLQNDR DRLLKELKNL QQQYLQINQE ITELHPLKAQ LQEYQDKTKA FQIMQEELRQ ENLSWQHELH QLRMEKSSWE IHERRMKEQY LMAISDKDQQ LSHLQNLIRE LRSSSSQTQP LKVQYQRQAS PETSASPDGS QNLVYETELL RTQLNDSLKE IHQKELRIQQ LNSNFSQLLE EKNTLSIQLC DTSQSLRENQ QHYGDLLNHC AVLEKQVQEL QAGPLNIDVA PGAPQEKNGV HRKSDPEELR EPQQSFSEAQ QQLCNTRQEV NELRKLLEEE RDQRVAAENA LSVAEEQIRR LEHSEWDSSR TPIIGSCGTQ EQALLIDLTS NSCRRTRSGV GWKRVLRSLC HSRTRVPLLA AIYFLMIHVL LILCFTGHL
Explore Golgin subfamily B member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets